Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001445305-13-000221
Filing Date
2013-02-14
Accepted
2013-02-14 16:12:10
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13g-ajkazimi2012.htm SC 13G 77491
  Complete submission text file 0001445305-13-000221.txt   78986
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filed by) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 13613899
SIC: 2834 Pharmaceutical Preparations